Seroepidemiology of Toxoplasma gondii infection in the Israeli population

Epidemiology and Infection

Volumn 142, Issue 1, 2014, Pages 149-155

  Markovich, M Perry ^a   Shohat, T ^a,b   Riklis, I ^c   Avni, R ^c   Yujelevski Rozenblit, D ^c   Bassal, R ^a,b   Cohen, D ^b   Rorman, E ^c  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c MINISTRY OF HEALTH   (Israel)

Author keywords

Arabs; Bedouins; Israel; Jews; Sera bank; Seroprevalence; Toxoplasma gondii

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY;

ADOLESCENT; ADULT; AGED; ARAB; ARTICLE; BLOOD SAMPLING; CLIMATE CHANGE; CONGENITAL TOXOPLASMOSIS; CONTROLLED STUDY; DISEASE PREDISPOSITION; ETHNIC DIFFERENCE; FEMALE; HUMAN; INFECTION RATE; INFECTION RISK; ISRAEL; JEW; MAJOR CLINICAL STUDY; MALE; MATERNAL AGE; MIDDLE AGED; POPULATION RESEARCH; PREGNANT WOMAN; RESIDENTIAL AREA; SEROEPIDEMIOLOGY; SEROPREVALENCE; SEX DIFFERENCE; SOCIAL STATUS; TOXOPLASMOSIS; YOUNG ADULT;

EID: 84890022030     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268813000903     Document Type: Article

References (27)

1. Hill D, Dubey J. Toxoplasma gondii: Transmission, diagnosis and prevention. Clinical Microbiology and Infection 2002; 8: 634-640
2. Rorman E, et al. Congenital toxoplasmosis - prenatal aspects of Toxoplasma gondii infection. Reproductive Toxicology 2006; 21: 458-472
3. Jones JL, et al. Toxoplasma gondii infection in the United States: Seroprevalence and risk factors. American Journal of Epidemiology 2001; 154: 357
4. Jones JL, et al. Toxoplasma gondii infection in the United States, 1999, 2004, decline from the prior decade. American Journal of Tropical Medicine and Hygiene 2007; 77: 405
5. Hofhuis A, et al. Decreased prevalence and age-specific risk factors for Toxoplasma gondii IgG antibodies in The Netherlands between 1995/1996 and 2006/2007. Epidemiology and Infection 2010; 24: 9
6. Berger F, et al. Toxoplasmosis among pregnant women in France: Risk factors and change of prevalence between 1995 and 2003. Revue d'E;pide;miologie et de Sante; Publique 2009; 57: 241-248
7. Birgisdo;ttir A, et al. Seroprevalence of Toxoplasma gondii in Sweden, Estonia and Iceland. Scandinavian Journal of Infectious Diseases 2006; 38: 625-631
8. Abu-Madi MA, Al-Molawi N, Behnke JM. Seroprevalence and epidemiological correlates of Toxoplasma gondii infections among patients referred for hospital-based serological testing in Doha, Qatar. Parasites & Vectors 2008; 1: 39
9. Bouhamdan SF, et al. Seroprevalence of Toxoplasma antibodies among individuals tested at hospitals and private laboratories in Beirut. Lebanese Medical Journal 2010; 58: 8-11
10. Franklin DM, Dror Z, Nishri Z. The prevalence and incidence of Toxoplasma antibodies in pregnant women. Israel Journal of Medical Sciences 1993; 29: 285-286
11. Nishri Z, et al. Toxoplasmosis in Israel, 1970-73: Evaluation of laboratory data. Israel Journal of Medical Sciences 1978; 14: 1039-1047
12. Nishri Z, et al. Prevalence of antibodies to Toxoplasma gondii in the Tel-Mond area. Israel Journal of Medical Sciences 1993; 29: 30-32
13. Raz R, et al. Seroprevalence of antibodies against Toxoplasma gondii among two rural populations in northern Israel. Israel Journal of Medical Sciences 1993; 29: 636
14. Anon. Statistical Abstract of Israel, 2008, 59th edn. Jerusalem: Central Bureau of Statistics, 2008
15. Calderaro A, et al. Laboratory diagnosis of Toxoplasma gondii infection. International Journal of Medical Sciences 2009; 6: 135-136
16. Calderaro A, et al. Evaluation of Toxoplasma gondii immunoglobulin G (IgG) and IgM assays incorporating the new Vidia analyzer system. Clinical and Vaccine Immunology 2008; 15: 1076-1079
17. Hofgärtner WT, et al. Detection of immunoglobulin G (IgG) and IgM antibodies to Toxoplasma gondii: Evaluation of four commercial immunoassay systems. Journal of Clinical Microbiology 1997; 35: 3313-3315
18. Mosti M, et al. A 4-year evaluation of toxoplasmosis seroprevalence in the general population and in women of reproductive age in central Italy. Epidemiology and Infection. Published online: 11 December 2012. doi:10.1017/S0950268812002841
19. Studenicova C, Bencaiova G, Holkova; R. Seroprevalence of Toxoplasma gondii antibodies in a healthy population from Slovakia. European Journal of Internal Medicine 2006; 17: 470-473
20. Mostafavi SN, et al. Seroepidemiology of Toxoplasma gondii infection in Isfahan province, central Iran: A population based study. Journal of Research in Medical Sciences 2011; 16: 496
21. Rosso F, et al. Prevalence of infection with Toxoplasma gondii among pregnant women in Cali, Colombia, South America. American Journal of Tropical Medicine and Hygiene 2008; 78: 504
22. Salant H, Spira DT. A cross-sectional survey of anti-Toxoplasma gondii antibodies in Jerusalem cats. Veterinary Parasitology 2004; 124: 167-177
23. Anon. Statistical Abstract of Israel, 2011, 62nd edn. Jerusalem: Central Bureau of Statistics, 2011
24. Jenum P, et al. Prevalence of Toxoplasma gondii specific immunoglobulin G antibodies among pregnant women in Norway. Epidemiology and Infection 1998; 120: 87-92
25. Sakikawa M, et al. Anti-Toxoplasma antibody prevalence, primary infection rate, and risk factors in a study of toxoplasmosis in 4,466 pregnant women in Japan. Clinical and Vaccine Immunology 2012; 19: 365-367
26. Pappas G, Roussos N, Falagas ME. Toxoplasmosis snapshots: Global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. International Journal for Parasitology 2009; 39: 1385-1394
27. Lopes AP, et al. Seroepidemiology of Toxoplasma gondii infection in women from the North of Portugal in their childbearing years. Epidemiology and Infection 2012; 140: 872-877